Pirfenidone alleviates interstitial lung disease in mice by inhibiting neutrophil extracellular trap formation and NLRP3 inflammasome activation
Pirfenidone alleviates ILD in a murine MAILD model by inhibiting NETs formation and NLRP3 inflammasome activation, suggesting that PFD might be a potential therapeutic agent for IIM-ILD.
Authors
- Jin Guo (ORCID: https://orcid.org/0000-0001-6015-8860)
- Jumei Yang
- Qiyan Su
- Yingyue Feng
- Sigong Zhang (ORCID: https://orcid.org/0000-0003-1565-1431)
- Jiarui Zhu (ORCID: https://orcid.org/0000-0001-6225-8910)
- Xi Cui (ORCID: https://orcid.org/0000-0003-0069-9985)
Institutions
- Gansu Province Computing Center (CN)
- Lanzhou University Second Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Clinical & Experimental Immunology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/cei/uxaf019
- Citations
- 4
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 6.07